Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Equity Issued and Repurchased Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Solid Biosciences (SLDB) Other financing activities (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Other financing activities for 4 consecutive years, with $286000.0 as the latest value for Q2 2024.

Quarterly Other financing activities changed N/A to $286000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2024, up 1680.84% year-over-year, with the annual reading at $5.1 million for FY2024, N/A changed from the prior year.
Other financing activities hit $286000.0 in Q2 2024 for Solid Biosciences, down from $4.8 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $4.8 million in Q1 2024 to a low of $286000.0 in Q2 2024.